After presenting data showing a very high response rate to a clinical-stage drug in early state development, shares in bluebird bio (NASDAQ: BLUE) jumped 32.6% in June, according to S&P Global Market Intelligence.
After presenting data showing a very high response rate to a clinical-stage drug in early state development, shares in bluebird bio (NASDAQ: BLUE) jumped 32.6% in June, according to S&P Global Market Intelligence.